Also known as Toviaz
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012.Source: Wikipedia
Estimated Total Cost: $118.84 for an average of 28 days supply
Patients are most commonly prescribed fesoterodine to treat frequent urination, involuntary urination, rabies, and blastomycosis.
Patients taking fesoterodine most commonly experience side effects like mouth dryness, constipation, and urinary tract infection.